Lilly Wins Axid Patent Ruling; Ivax Directed To Pay Attorneys Fees
Executive Summary
Ivax must pay Lilly's attorney fees after a court ruling found that its challenge of the Axid (nizatidine) chemical compound patent was not based on "reasonable and good faith" assumptions
You may also be interested in...
Zyprexa Willful Infringement Claim Dismissal Could Speed Ivax Launch
Ivax said it is more likely to launch its generic of the antipsychotic Zyprexa ahead of an appellate court decision now that Lilly has agreed to dismiss a willful infringement claim prior to trial
Zyprexa Willful Infringement Claim Dismissal Could Speed Ivax Launch
Ivax said it is more likely to launch its generic of the antipsychotic Zyprexa ahead of an appellate court decision now that Lilly has agreed to dismiss a willful infringement claim prior to trial
Generic Firms Warned Of First-To-File Risk: Willful Infringement Cases Rising
The pressure on generic companies to be first-to-file in patent challenges will lead to a "boom" in willful infringement cases against generics makers, an industry attorney maintains